Focus Partners Wealth Sells 1,833 Shares of Hologic, Inc. $HOLX

Focus Partners Wealth decreased its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 6.1% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 28,126 shares of the medical equipment provider’s stock after selling 1,833 shares during the period. Focus Partners Wealth’s holdings in Hologic were worth $1,737,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of HOLX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Hologic by 2.5% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,256 shares of the medical equipment provider’s stock valued at $2,542,000 after acquiring an additional 869 shares during the period. Nomura Holdings Inc. purchased a new position in shares of Hologic during the 4th quarter valued at $551,000. ProShare Advisors LLC lifted its stake in shares of Hologic by 9.7% during the 4th quarter. ProShare Advisors LLC now owns 42,164 shares of the medical equipment provider’s stock valued at $3,040,000 after buying an additional 3,714 shares in the last quarter. Raiffeisen Bank International AG purchased a new position in shares of Hologic during the 4th quarter valued at $49,000. Finally, Rafferty Asset Management LLC lifted its stake in shares of Hologic by 11.8% during the 4th quarter. Rafferty Asset Management LLC now owns 26,347 shares of the medical equipment provider’s stock valued at $1,899,000 after buying an additional 2,788 shares in the last quarter. Institutional investors own 94.73% of the company’s stock.

Analysts Set New Price Targets

HOLX has been the topic of several research analyst reports. UBS Group boosted their price target on shares of Hologic from $65.00 to $70.00 and gave the stock a “neutral” rating in a research note on Thursday, July 31st. Morgan Stanley boosted their price target on shares of Hologic from $65.00 to $69.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 31st. Needham & Company LLC reiterated a “hold” rating on shares of Hologic in a research note on Tuesday, May 27th. Evercore ISI boosted their price target on shares of Hologic from $62.00 to $68.00 and gave the stock an “in-line” rating in a research note on Tuesday, July 8th. Finally, Mizuho set a $75.00 price target on shares of Hologic in a research note on Thursday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and eight have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $78.00.

Hologic Trading Down 0.7%

Shares of Hologic stock opened at $63.33 on Wednesday. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. The firm has a fifty day moving average price of $66.38 and a 200 day moving average price of $62.65. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $84.39. The stock has a market cap of $14.09 billion, a PE ratio of 26.28, a price-to-earnings-growth ratio of 2.31 and a beta of 0.57.

Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.05 by $0.03. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The company’s revenue for the quarter was up 1.2% compared to the same quarter last year. During the same quarter last year, the business earned $1.06 earnings per share. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Equities research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.